Patents by Inventor Mohamed Helmi Zaghdane

Mohamed Helmi Zaghdane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8637671
    Abstract: Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: January 28, 2014
    Assignee: Merck Canada Inc.
    Inventors: John Colucci, Michael Boyd, Mohamed Helmi Zaghdane, Michel Gallant
  • Patent number: 8546422
    Abstract: Compounds of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: October 1, 2013
    Assignee: Merck Canada Inc.
    Inventors: Yves Leblanc, Carl Berthelette, Daniel Simard, Mohamed Helmi Zaghdane
  • Publication number: 20110178115
    Abstract: Compounds of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.
    Type: Application
    Filed: September 17, 2009
    Publication date: July 21, 2011
    Applicant: Merck Frosst Canada Ltd
    Inventors: Yves Leblanc, Carl Berthelette, Daniel Simard, Mohamed Helmi Zaghdane
  • Publication number: 20110172263
    Abstract: Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.
    Type: Application
    Filed: September 17, 2009
    Publication date: July 14, 2011
    Applicant: MERCK FROSST CANADA LTD
    Inventors: John Colucci, Michael Boyd, Mohamed Helmi Zaghdane, Michel Gallant